Cytovance Biologics Announces Business Development Focus in International Markets and Promotion of New Vice President of Sales & Business Development - North America

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance® Biologics LLC announced today that it is launching dedicated business development activities in International markets for biologic contract manufacturing of therapeutic proteins and monoclonal antibodies. In a newly created position, Molly S. McGlaughlin MeD, has been appointed as Vice President of Sales & Business Development – International, and will be spearheading this critical strategic growth initiative. Molly joined Cytovance in 2008 as Vice President of Sales & Business Development and rapidly established Cytovance as a premier biologics contract manufacturing organization in providing a comprehensive menu of biopharmaceutical development and cGMP manufacturing services. Molly and her team were responsible for the robust revenue growth through securing custom-designed development and manufacturing agreements with numerous clients.